Why it matters
The program may create one of the clearest U.S. precedents for linking existing therapeutics, healthspan endpoints, and a regulatory pathway.
Decision implication
Track protocol, endpoints, regulatory interactions, safety management, and whether results support an aging/healthspan indication pathway.
Who or what is affected
- ARPA-H
- UT Health San Antonio
- FDA
- trial sites
- biopharma
- patients
Evidence and sources
Decision priority: Watch
Source authority: Primary/authoritative · official federal award description
Evidence design: Program record
Applicability: Direct
Confidence for the stated claim: High
Freshness: Current
P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.
For this decision
Researchers · Innovators · Funders/investors · Policymakers · Clinicians
What P4L is watching next
- Trial initiation
- endpoint selection
- FDA engagement
- outcome data.
Related proof records
Record provenance
- Last verified
- 2026-09-03
- Source date (award start)
- 2026-02-24
- Revision state
- Version 1.1 strengthens the prospective-trial and existing-approval limits and records the September 3, 2026 re-verification; no result is reported.
- Status
- Current ARPA-H award description · phase 3 hybrid trial prospective · no results reported
- Freshness
- Current
- Version
- 1.1
- Stable ID
- SIG-2026-007